低剂量碘斑块近距离放疗治疗邻视乳头脉络膜黑色素瘤的疗效与安全性
回顾性介入病例系列纳入47例邻视乳头脉络膜黑色素瘤患者,按顶点剂量中位数84.35 Gy分为低剂量组和高剂量组,比较碘-125斑块近距离放疗的远处失败、局部失败、死亡、眼球摘除、放射性视网膜病变、视神经病变及视力结局;低剂量组放射性视网膜病变和视神经病变的5年、10年无事件率更高,5 mm低剂量组视力结局更有利,但顶点低剂量与高剂量组视力结局无差异。
要点
- 顶点低剂量组与高剂量组5年远处失败无事件率分别为96%和95%,10年分别为77%和95%(P = .84)。
- 顶点低剂量组与高剂量组5年和10年局部失败无事件率分别为90%和89%(P = .96)。
- 顶点低剂量组放射性视网膜病变和视神经病变的5年、10年无事件率高于高剂量组。
核心结论
- 低剂量碘-125斑块近距离放疗(肿瘤顶点67.5-81 Gy)为邻视乳头脉络膜黑色素瘤提供安全有效的肿瘤控制,并可能与放射性毒性降低相关。
- 需要更大规模试验来确定邻视乳头脉络膜黑色素瘤的最佳治疗剂量。
研究设计与样本
- 回顾性介入病例系列,单机构设置,纳入47例邻视乳头脉络膜黑色素瘤患者。
- 干预为碘-125斑块近距离放疗,按顶点剂量中位数84.35 Gy将患眼分为顶点低剂量组(≤84.35 Gy)和高剂量组(>84.35 Gy)。
- 主要结局指标为至远处失败、局部失败、死亡、眼球摘除、放射性视网膜病变、视神经病变和最佳矫正视力(BCVA)的时间。
主要发现
- 顶点低剂量组与高剂量组5年远处失败无事件率分别为96%和95%,10年分别为77%和95%(P = .84)。
- 顶点低剂量组与高剂量组5年和10年局部失败无事件率分别为90%和89%(P = .96)。
- 顶点低剂量组与高剂量组至死亡时间和至眼球摘除时间无差异。
- 顶点低剂量组放射性视网膜病变和视神经病变的5年、10年无事件率高于高剂量组。
- 5 mm低剂量组相比高剂量组,BCVA下降≥3行、最终BCVA 20/40或更好、最终BCVA 20/200或更差等视力结局更有利;顶点低剂量组与高剂量组视力结局无差异。
关键数值与推荐
- 顶点低剂量组定义为顶点剂量≤中位数84.35 Gy,高剂量组定义为顶点剂量>中位数84.35 Gy。
- 低剂量碘-125斑块近距离放疗的肿瘤顶点剂量范围为67.5-81 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate low- vs high-dose plaque brachytherapy for juxtapapillary choroidal melanoma. DESIGN: Retrospective interventional case series. METHODS: Setting: Single institution. STUDY POPULATION: Forty-seven patients with juxtapapillary choroidal melanoma. INTERVENTION: Iodine-125 plaque brachytherapy. Eyes were divided into apex low-dose (LD) and high-dose (HD) groups (≤ or > median apex dose 84.35 Gy). Main outcome measures were time to distant failure, local failure, death, enucleation, radiation retinopathy, optic neuropathy, and best-corrected visual acuity (BCVA). RESULTS: Freedom from distant failure rates were 96% and 95% in apex LD and HD groups at 5 years and 77% and 95% at 10 years, respectively (P = .84). Freedom from local failure rates were 90% in the apex LD group vs 89% in the HD group at 5 and 10 years (P = .96). Apex LD and HD groups did not differ for time to death or enucleation. Five- and 10-year freedom from radiation retinopathy and optic neuropathy rates were higher in the apex LD than HD group. Loss of ≥3 BCVA lines, final BCVA 20/40 or better, and final BCVA 20/200 or worse were more favorable in the 5 mm LD compared to HD group. Visual acuity outcomes did not differ between apex LD and HD groups. CONCLUSIONS: Low-dose iodine-125 plaque brachytherapy (67.5-81 Gy at tumor apex) provides safe and effective tumor control for juxtapapillary choroidal melanoma and may be associated with reduced radiation toxicity. Larger trials are needed to determine the optimal therapeutic dose for juxtapapillary choroidal melanoma.
引用
- Oellers P, Mowery YM, Perez BA, et al. Efficacy and Safety of Low-Dose Iodine Plaque Brachytherapy for Juxtapapillary Choroidal Melanoma. Am J Ophthalmol. 2017. PMID: 29199010. doi:10.1016/j.ajo.2017.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。